On 31 March, Anavex Life Sciences Corp - a clinical-stage biopharmaceutical company developing therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease (AD) - announced that the Independent Data Safety Monitoring Board (DSMB) has greenlighted the company to continue, without changes, its Phase IIb/III clinical trial of ANAVEX2-73 in people with AD. The DSMB has completed its recent pre-planned review of the preliminary safety data of the Phase IIb/III clinical study ANAVEX®2-73-AD-004 and its Open Label Extension ANAVEX®2-73-AD-EP-004 ATTENTION-AD study.
The 48- weeks ANAVEX®2-73-AD-004 clinical study is a Phase IIb/III double-blind, randomised and placebo-controlled study evaluating the safety and efficacy of ANAVEX®2-73 for the treatment of early AD. This ongoing trial has more than 90% of the 450 research participants enrolled. Primary and secondary endpoints will assess safety and both cognitive and functional efficacy.
